cisplatin concentrate for soln for inf 1mg/ml (50ml vial)
fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents
cisplatin concentrate for soln for inf 1mg/ml (100ml vial)
fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/5ml - antineoplastic agents
cisplatin teva concentrate for soln for inf 1mg/ml (10mg vial)
teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents
imatinib actavis group 100mg film-coated tablets
actavis group ptc ehf - imatinib mesilate - film-coated tablet - 100 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib actavis group is indicated for the treatment of - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult patients with ph+ cml in blast crisis. - adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement.
imatinib actavis group 400mg film-coated tablets
actavis group ptc ehf - imatinib mesylate - film-coated tablet - 400 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib actavis group is indicated for the treatment of - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult patients with ph+ cml in blast crisis. - adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement.
imatinib clonmel 100 mg film-coated tablets
clonmel healthcare ltd - imatinib - film-coated tablet - 100 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib clonmel is indicated in: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosino
imatinib clonmel 400 mg film-coated tablets
clonmel healthcare ltd - imatinib - film-coated tablet - 400 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib clonmel is indicated in: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement.
cisplatin teva concentrate for soln for inf 1mg/ml (50mg vial)
teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents
cisplatin teva concentrate for soln for inf 1mg/ml (100mg vial)
teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents
campto 20 mg/ml concentrate for solution for infusion (2ml vial)
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan - concentrate for solution for infusion - irinotecan 20 mg/ml - antineoplastic agents